FR2989280B1 - Nanoparticules ultrafines comme agent de contraste multimodal - Google Patents

Nanoparticules ultrafines comme agent de contraste multimodal

Info

Publication number
FR2989280B1
FR2989280B1 FR1253438A FR1253438A FR2989280B1 FR 2989280 B1 FR2989280 B1 FR 2989280B1 FR 1253438 A FR1253438 A FR 1253438A FR 1253438 A FR1253438 A FR 1253438A FR 2989280 B1 FR2989280 B1 FR 2989280B1
Authority
FR
France
Prior art keywords
contrast agent
ultrafine nanoparticles
multimodal contrast
multimodal
ultrafine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1253438A
Other languages
English (en)
French (fr)
Other versions
FR2989280A1 (fr
Inventor
Yannick Cremillieux
Andrea Bianchi
Sandrine Dufort
Jean-Luc Coll
Francois Lux
Olivier Tillement
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique
Université de Bordeaux
Grenoble Alpes University
Nano H SAS
Université Claude Bernard Lyon 1
Original Assignee
Centre National de la Recherche Scientifique
Joseph Fourier University
Nano H SAS
Université Claude Bernard Lyon 1
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR1253438A priority Critical patent/FR2989280B1/fr
Application filed by Centre National de la Recherche Scientifique, Joseph Fourier University, Nano H SAS, Université Claude Bernard Lyon 1 filed Critical Centre National de la Recherche Scientifique
Priority to JP2015504970A priority patent/JP6368301B2/ja
Priority to EP13718146.7A priority patent/EP2836237B1/fr
Priority to ES13718146T priority patent/ES2791224T3/es
Priority to DK13718146.7T priority patent/DK2836237T3/da
Priority to CA2869689A priority patent/CA2869689C/fr
Priority to PCT/EP2013/057677 priority patent/WO2013153197A1/fr
Priority to US14/394,004 priority patent/US10517962B2/en
Priority to EP20156278.2A priority patent/EP3689384A1/fr
Publication of FR2989280A1 publication Critical patent/FR2989280A1/fr
Priority to JP2016253238A priority patent/JP6385420B2/ja
Application granted granted Critical
Publication of FR2989280B1 publication Critical patent/FR2989280B1/fr
Priority to US16/705,305 priority patent/US11529316B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/103—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
    • A61K49/105—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA the metal complex being Gd-DTPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A61K49/108—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA the metal complex being Gd-DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/183—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an inorganic material or being composed of an inorganic material entrapping the MRI-active nucleus, e.g. silica core doped with a MRI-active nucleus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • A61K51/1244—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nanotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Ceramic Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
FR1253438A 2012-04-13 2012-04-13 Nanoparticules ultrafines comme agent de contraste multimodal Active FR2989280B1 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
FR1253438A FR2989280B1 (fr) 2012-04-13 2012-04-13 Nanoparticules ultrafines comme agent de contraste multimodal
EP20156278.2A EP3689384A1 (fr) 2012-04-13 2013-04-12 Nanoparticules ultrafines comme agent de contraste multimodal
ES13718146T ES2791224T3 (es) 2012-04-13 2013-04-12 Nanopartículas ultrafinas como agente de contraste multimodal
DK13718146.7T DK2836237T3 (da) 2012-04-13 2013-04-12 Ultrafine nanopartikler som multimodalt kontrastmiddel
CA2869689A CA2869689C (fr) 2012-04-13 2013-04-12 Nanoparticules ultrafines comme agent de contraste multimodal
PCT/EP2013/057677 WO2013153197A1 (fr) 2012-04-13 2013-04-12 Nanoparticules ultrafines comme agent de contraste multimodal
JP2015504970A JP6368301B2 (ja) 2012-04-13 2013-04-12 マルチモーダル造影剤としての超微細ナノ粒子
EP13718146.7A EP2836237B1 (fr) 2012-04-13 2013-04-12 Nanoparticules ultrafines comme agent de contraste multimodal
US14/394,004 US10517962B2 (en) 2012-04-13 2013-04-12 Ultrafine nanoparticles as multimodal contrast agent
JP2016253238A JP6385420B2 (ja) 2012-04-13 2016-12-27 マルチモーダル造影剤としての超微細ナノ粒子
US16/705,305 US11529316B2 (en) 2012-04-13 2019-12-06 Ultrafine nanoparticles as multimodal contrast agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1253438A FR2989280B1 (fr) 2012-04-13 2012-04-13 Nanoparticules ultrafines comme agent de contraste multimodal

Publications (2)

Publication Number Publication Date
FR2989280A1 FR2989280A1 (fr) 2013-10-18
FR2989280B1 true FR2989280B1 (fr) 2017-02-24

Family

ID=48170443

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1253438A Active FR2989280B1 (fr) 2012-04-13 2012-04-13 Nanoparticules ultrafines comme agent de contraste multimodal

Country Status (8)

Country Link
US (2) US10517962B2 (cg-RX-API-DMAC10.html)
EP (2) EP2836237B1 (cg-RX-API-DMAC10.html)
JP (2) JP6368301B2 (cg-RX-API-DMAC10.html)
CA (1) CA2869689C (cg-RX-API-DMAC10.html)
DK (1) DK2836237T3 (cg-RX-API-DMAC10.html)
ES (1) ES2791224T3 (cg-RX-API-DMAC10.html)
FR (1) FR2989280B1 (cg-RX-API-DMAC10.html)
WO (1) WO2013153197A1 (cg-RX-API-DMAC10.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3192530A1 (fr) * 2016-01-15 2017-07-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nanoparticules ultrafines comme agent d'imagerie pour el diagnostic d'une dysfonction rénale
AU2017371069C1 (en) * 2016-12-08 2025-02-27 Centre National De La Recherche Scientifique Bismuth-gadolinium nanoparticles
CN110933934A (zh) * 2017-06-09 2020-03-27 Nh阿吉克斯治疗公司 用于合成二氧化硅纳米颗粒的方法
FR3072281B1 (fr) 2017-10-13 2020-12-04 Nh Theraguix Nanovecteurs et utilisations, en particulier pour le traitement de tumeurs
FR3075649A1 (fr) * 2017-12-22 2019-06-28 Mexbrain Dispositif pour le maintien de l'homeostasie metallique, et ses utilisations
WO2020249818A1 (en) * 2019-06-14 2020-12-17 Advanced Accelerator Applications Method of treating cancer by intratumoral deposition of radioactive microparticles
FR3099883A1 (fr) * 2019-08-14 2021-02-19 Nh Theraguix Nanoparticules pour le traitement du cancer par rayonnement de radiofréquence
DE102019128842A1 (de) * 2019-10-25 2021-04-29 Universität Hamburg Verfahren, Vorrichtung und Markersubstanz-Kit zur multiparametrischen Röntgenfluoreszenz-Bildgebung
IT202000001048A1 (it) 2020-01-21 2021-07-21 Univ Degli Studi Padova Nanoparticelle multifunzionali a base di nanoleghe metalliche per usi diagnostici e terapeutici.
JP7479606B2 (ja) * 2020-05-19 2024-05-09 国立研究開発法人産業技術総合研究所 放射性組成物の製造方法
FR3116197A1 (fr) * 2020-11-19 2022-05-20 Nh Theraguix Procédé de traitement de tumeurs par captation du cuivre et/ou du fer
IT202100001049A1 (it) 2021-01-21 2022-07-21 Univ Degli Studi Padova Nanoparticelle multifunzionali a base di nanoleghe metalliche per usi diagnostici e terapeutici.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2795412B1 (fr) 1999-06-23 2001-07-13 Adir Nouveaux derives d'ammonium quaternaire, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP4657721B2 (ja) 2002-09-19 2011-03-23 センター ナショナル デ ラ レシェルシェ サイエンティフィック（シーエヌアールエス） 新規な誘導システムの合成及び特徴付け、並びに標的細胞への治療対象分子のベクター化
FR2867180B1 (fr) 2004-03-02 2006-06-16 Univ Claude Bernard Lyon Nanoparticules hybrides comprenant un coeur de ln203 porteuses de ligands biologiques et leur procede de preparation
EP1756289B1 (en) 2004-05-24 2015-01-14 Midatech Ltd. Nanoparticles comprising rna ligands
US20090317335A1 (en) * 2006-04-20 2009-12-24 Wenbin Lin Hybrid Nanomaterials as Multimodal Imaging Contrast Agents
FR2922106B1 (fr) 2007-10-16 2011-07-01 Univ Claude Bernard Lyon Utilisation de nanoparticules a base de lanthanides comme agents radiosensibilisants.
WO2009129482A1 (en) * 2008-04-17 2009-10-22 Duke University Methods and compositions for molecular imaging
FR2959502B1 (fr) 2010-04-30 2012-09-07 Nanoh Nanoparticules ultrafines a matrice polyorganosiloxane fonctionnalisee et incluant des complexes metalliques ; leur procede d'obtention et leurs applications en imagerie medicale et/ou therapie
US8688121B2 (en) 2010-04-30 2014-04-01 Blackberry Limited UE handling of common configuration after handover

Also Published As

Publication number Publication date
US11529316B2 (en) 2022-12-20
CA2869689C (fr) 2023-03-14
US10517962B2 (en) 2019-12-31
FR2989280A1 (fr) 2013-10-18
US20200108155A1 (en) 2020-04-09
CA2869689A1 (fr) 2013-10-17
JP6368301B2 (ja) 2018-08-01
JP6385420B2 (ja) 2018-09-05
WO2013153197A1 (fr) 2013-10-17
EP2836237B1 (fr) 2020-04-01
EP2836237A1 (fr) 2015-02-18
JP2017095480A (ja) 2017-06-01
DK2836237T3 (da) 2020-05-25
US20150050217A1 (en) 2015-02-19
EP3689384A1 (fr) 2020-08-05
JP2015518478A (ja) 2015-07-02
ES2791224T3 (es) 2020-11-03

Similar Documents

Publication Publication Date Title
EP2848334A4 (en) HOLLOW METAL NANOPARTICLES
EP2833926A4 (en) NEUROPHILIC NANOPARTICLES
GB201005601D0 (en) Ecapsulated nanoparticles
EP2575772A4 (en) MAGNETIC NANOPARTICLES
GB201200355D0 (en) Nanowires
GB201215289D0 (en) Nanoparticle formulation
EP2872120A4 (en) TARGETED THERAPEUTIC NANOPARTICLES
SG11201502441SA (en) Metal nanoparticles formed around a nucleus
FR2975090B1 (fr) Nanoparticules autodispersantes
PT2878950T (pt) Biosensor compreendendo nanopartículas metálicas
SG11201503403QA (en) Encapsulated Nanoparticles
DK2836237T3 (da) Ultrafine nanopartikler som multimodalt kontrastmiddel
SG11201501382YA (en) Nanoparticulate contrast agent
EP2648764A4 (en) MULTIFUNCTIONAL NANOPARTICLES
EP2880250A4 (en) Remote activated deflector
ZA201500175B (en) Hydrophobic coating
FR2987356B1 (fr) Formation de nanoparticules d'antimoniures a partir du trihydrure d'antimoine comme source d'antimoine.
EP2481088A4 (en) PASSIVATED NANOPARTICLES
EP2990137A4 (en) Metal nanoparticles
GB201216930D0 (en) Nanoparticles
FR2955038B1 (fr) Nanoparticules anti-uv
EP2630078A4 (en) NANOSCALE STRUCTURES
EP2990139A4 (en) Metal nanoparticles
PL2631209T3 (pl) Żuraw
BR112013004785A2 (pt) agente citoprotetor

Legal Events

Date Code Title Description
TQ Partial transmission of property

Owner name: UNIVERSITE JOSEPH FOURIER, FR

Effective date: 20140409

Owner name: UNIVERSITE BORDEAUX SEGALEN, FR

Effective date: 20140409

Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE -, FR

Effective date: 20140409

Owner name: UNIVERSITE CLAUDE BERNARD LYON I, FR

Effective date: 20140409

Owner name: NANO-H, FR

Effective date: 20140409

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 8

PLFP Fee payment

Year of fee payment: 9

AU Other action affecting the ownership or exploitation of an industrial property right

Effective date: 20201207

CL Concession to grant licences

Name of requester: PULSALYS, FR

Effective date: 20201207

TQ Partial transmission of property

Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE -, FR

Effective date: 20201207

Owner name: UNIVERSITE GRENOBLE ALPES, FR

Effective date: 20201207

Owner name: NANO-H, FR

Effective date: 20201207

Owner name: UNIVERSITE CLAUDE BERNARD LYON I, FR

Effective date: 20201207

Owner name: UNIVERSITE DE BORDEAUX, FR

Effective date: 20201207

PLFP Fee payment

Year of fee payment: 10

PLFP Fee payment

Year of fee payment: 11

PLFP Fee payment

Year of fee payment: 12

PLFP Fee payment

Year of fee payment: 13

PLFP Fee payment

Year of fee payment: 14

PLFP Fee payment

Year of fee payment: 15